Targeting DHFR to suppress one-carbon metabolism and enhance radiation sensitivity in patients with NRF2-active head and neck squamous cell carcinoma.
In HNSCC patients, pyrimethamine achieves potent DHFR inhibition and a favorable safety profile supporting a future phase 2 trial integrating pyrimethamine with definitive radiation-based therapy for NRF2-active HNSCCs.